Overactive bladder
Template:SignSymptom infobox Template:Search infobox Steven C. Campbell, M.D., Ph.D.
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia." The International Continence Society(ICS) is responsible for this definition. There exists, however, some controversy over the use of this term because these symptoms taken in isolation may overlap with those of other bladder conditions, including interstitial cystitis, or rarely even bladder tumours.
Pathophysiology
The etiology of OAB is unclear, and indeed there may be multiple possible causes. It is often associated with detrusor overactivity, a pattern of bladder muscle contraction observed during urodynamics, and treatments for OAB, are usually synonymous with treatments for detrusor overactivity. OAB is distinct from stress urinary incontinence, but when they occur together is usually known as mixed incontinence.
Epidemiology and demographics
Earlier reports estimated that about one in six adults in the United States or Europe had OAB.[1][2] Because the average age of people in the developed world is increasing, it is expected that OAB will become more common in the future as the prevalence of OAB increases with age.[1][2] However, a recent Finnish population-based survey[3] showed that the prevalence had been largely overestimated due to methodological shortcomings regarding age distribution and low participation (in earlier reports). OAB affects approximately half of that proposed earlier.[3]
Treatment
Treatment for OAB includes lifestyle modification (fluid restriction, avoidance of caffeine), bladder retraining, antimuscarinic drugs (darifenacin, hyoscyamine, oxybutynin, tolterodine, solifenacin, trospium), and various devices (Urgent PC Neuromodulation System, InterStim). Intravesical botulinum toxin A is also used in some intractable cases, although not with formal FDA approval. The antimuscarinic fesoterodine was recommended for approval by the European Medicines Agency in February 2007, and will become available for use during 2008.
References
- ↑ 1.0 1.1 "Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States World Journal of Urology 2003 May;20(6):327-36" (PDF).
- ↑ 2.0 2.1 Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760-6.
- ↑ 3.0 3.1 "Tikkinen KAO, Tammela TLJ, Rissanen AM, Valpas A, Huhtala H, Auvinen A. Is the Prevalence of Overactive Bladder Overestimated? A Population-Based Study in Finland PLoS ONE 2007 2(2):e195".
Support Resources
- Incontact.org
- The Continence Foundation
- Cystitis & Overactive Bladder Foundation - UK
- Canada IC & OAB Resource Center
Information Resources
- Overcoming Overactive Bladder
- Interstitial Cystitis Survival Guide